Disc Medicine, Inc. announced that it has raised $53.5 million in a round of funding led by returning investor Access Biotechnology on December 29, 2022. The transaction also included participation from returning investors Novo Holdings A/S,Atlas Venture L.P.,OrbiMed Advisors LLC,Arix Bioscience plc,5AM Venture Management, LLC,Rock Springs Capital Management LP and Janus Henderson Group plc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.79 USD | +2.72% | +8.13% | -48.42% |
08/04 | Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating | MT |
02/04 | Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
32.55 USD | +1.85% | +2.71% | 5.22B | ||
29.79 USD | +2.72% | +8.13% | 736M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-48.42% | 736M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- IRON Stock
- News Disc Medicine, Inc.
- Disc Medicine, Inc. announced that it has received $53.5 million in funding from a group of investors